Skip to main content

Digoxin

FDA recalls

2 rows

DateCompany and reasonClass
Mar 24, 2024Novitium Pharma LLC
Failed Impurities/Degradation Specifications
Class III · Terminated
Mar 3, 2024Novitium Pharma LLC
Cross Contamination with Other Products:(mycophenolate mofetil).
Class III · Terminated

← Back to Digoxin

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).